Widespread acceptance of liquid biopsy technique in North America and steady adoption in developing regions is expected to drive global liquid biopsy market revenues. The global market is expected to reach US$ 407 Mn in 2016, up from US$ 351 Mn in 2015. North America will continue to remain the largest market for liquid biopsy, accounting for over 50% share of the global market.
The minimally-invasive nature and economical affordability of liquid biopsy tests will play a key role in bolstering demand globally. FDA approvals for non-invasive diagnostic tests for cancers is expected to have a positive influence on the growth of the market.
In terms of value, North America is estimated to be the dominant market in 2016, which is expected to expand at a CAGR of 21.3% over the forecast period. APEJ is estimated to be the fastest growing markets in terms of revenue growth. APEJ liquid biopsy market is expected to register a CAGR of 25.5% over the forecast period. Lung cancer disease indication segment in the APEJ liquid biopsy market is expected to register a CAGR of 22.0% over the forecast period, with growth driven by increasing prevalence of lung cancer in the region.
Some of the key players in the global liquid biopsy market include Genomic Health, Inc., Biocept, Qiagen, Inc., Trovagene, Inc., F. Hoffmann-La Roche Ltd., Silicon Biosystems, Pathway Genomics Corporation, and Sysmex Corporation.
Report Overview, with TOC @ https://www.futuremarketinsights.com/reports/liquid-biopsy-market/toc